Statements (91)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:advocacy |
supportive
|
| gptkbp:awards |
Best Places to Work
Innovative Company Award biotechnology innovation awards |
| gptkbp:business_model |
biotech startup
|
| gptkbp:ceo |
Steve Harr
|
| gptkbp:clinical_trial |
ongoing
Phase 1 Phase 2 Phase 3 promising |
| gptkbp:collaboration |
biopharmaceutical companies
|
| gptkbp:collaborations |
international
academic institutions research hospitals |
| gptkbp:community_engagement |
active
patient advocacy groups |
| gptkbp:community_outreach |
active programs
|
| gptkbp:development |
innovative solutions
|
| gptkbp:focus |
gptkb:gene_therapy
|
| gptkbp:founded |
gptkb:2018
|
| gptkbp:founder |
Steve Harr
|
| gptkbp:funding |
gptkb:venture_capital
grants government grants philanthropic donations |
| gptkbp:future_goals |
improve patient outcomes
develop new therapies expand clinical trials |
| gptkbp:future_plans |
enhance technology
expand pipeline increase collaborations |
| gptkbp:has_advisory_board |
established
experts in gene therapy |
| gptkbp:headquarters |
gptkb:San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sana Therapeutics
|
| gptkbp:instruction_set |
multiple candidates
|
| gptkbp:invention |
gene therapy technologies
multiple granted |
| gptkbp:investment |
gptkb:Sofinnova_Partners
gptkb:Canaan_Partners gptkb:Orbi_Med_Advisors transparent |
| gptkbp:investment_focus |
global
biopharmaceutical industry |
| gptkbp:is_a_platform_for |
gptkb:Cell
gene editing gene replacement therapy |
| gptkbp:is_collaborative_with |
academic institutions
|
| gptkbp:leadership |
experienced professionals
experienced team |
| gptkbp:mission |
transform lives through gene therapy
|
| gptkbp:number_of_employees |
50-100
growing team |
| gptkbp:partnership |
gptkb:Duke_University
gptkb:University_of_California,_San_Francisco research organizations |
| gptkbp:partnerships |
pharmaceutical companies
|
| gptkbp:publications |
numerous
peer-reviewed journals |
| gptkbp:regulatory_compliance |
FDA approved
|
| gptkbp:research |
therapeutic development
|
| gptkbp:research_and_development |
active
|
| gptkbp:research_areas |
genetic disorders
metabolic disorders oncology rare diseases cardiovascular diseases cellular therapies |
| gptkbp:research_focus |
gptkb:muscular_dystrophy
genetic disorders rare diseases central nervous system muscle diseases |
| gptkbp:social_responsibility |
committed
healthcare access initiatives |
| gptkbp:targets |
neurological disorders
neuromuscular diseases muscle disorders |
| gptkbp:technology |
gptkb:CRISPR
AAV gene delivery AAV-based gene delivery RNA therapy |
| gptkbp:values |
gptkb:collaboration
innovation integrity patient-centric approach |
| gptkbp:vision |
leading gene therapy company
treating genetic diseases |
| gptkbp:website |
www.sanatherapeutics.com
|